

Author Index

- Abuhamad, A. Z., 264
 Aghajafari, F., 341
 Al-Saif, S., 100
 Alvaro, R., 100
 Amankwah, K. S., 310
 Aranda, J. V., 65
 Asselin, P., 70
 Bernier, S. G., 70
 Besinger, R. E., 316
 Bhattacharya, M., 70
 Bouayad, A., 70
 Briet, J. M., 417
 Brosnan, P. G., 371
 Bukowski, R., 272
 Cates, D., 100
 Caughey, A. B., 248
 Chaikin, S., 107
 Chemtob, S., 70
 Chessex, P., 55
 Chou, S.-J., 94
 Clyman, R. I., 70
 Contag, C. H., 85
 Divon, M. Y., 44
 Duff, P., 295
 Economy, K. E., 264
 Escande, B., 76
 Fanaroff, A. A., 107
 Fant, M. E., 426
 Ferber, A., 44
 Forcelledo, M. L., 363
 Fouron, J.-C., 70
 Fung, Y. S., 50
 Gianopoulos, J. G., 316
 Glibetic, M., 65
 Gross, I., 406
 Guerguerian, A.-M., 70
 Guignard, J.-P., 49
 Hannah, M., 341
 Hardy, P., 70
 Helwig, J.-J., 76
 Hsieh, F.-J., 3
 Huisman, T. W. A., 21
 Jacobs, M., 107
 Jaffe, R., 1, 3
 Kennedy, K. A., 397
 Kiserud, T., 11
 Kiwi, R., 107
 Kok, J. H., 417
 Kwiatkowski, K., 100
 Laborie, S., 55
 Landen, C. N., Jr., 256
 Lavoie, J.-C., 55
 Lin, C.-h., 94
 Lindner, V., 76
 Llanos, A., 436
 Locksmith, G., 295
 Lorenz, J. M., 348
 Manfreda, J., 100
 Massfelder, T., 76
 Mastrobattista, J. M., 385
 Matias, A., 32
 Mauldin, J. G., 215
 Maxwell, C. V., 310
 Mena, P., 436
 Mittendorf, R., 316
 Montenegro, N., 32
 Moya, F. R., 361, 406
 Murphy, K., 341
 Newman, R. B., 215
 Norwitz, E. R., 203, 204, 223, 263
 Ofenstein, J., 65
 Parer, J. T., 248
 Pomeranets, S., 107
 Pooh, K. H., 38
 Pooh, R. K., 38
 Pryde, P. G., 316
 Quiniou, C., 70
 Ramsey, P. S., 236
 Raykova, V., 65
 Regan, J. A., 204
 Rigatto, H., 100
 Robinson, J. N., 203, 204, 223, 263
 Rouleau, T., 55
 Rouse, D. J., 236
 Saade, G. R., 272
 Samlalsingh-Parker, J., 65
 Serón-Ferre, M., 363
 Share, L., 107
 Shih, J.-C., 3
 Simeoni, U., 76
 Stevenson, D. K., 85
 Sun, D. X., 50
 Torres-Farfán, C., 363
 Tsai, M.-L., 94
 Uauy, R., 436
 Valenzuela, G. J., 363
 Van Wassenae, A. G., 417
 Varma, D. R., 70
 Vermillion, S. T., 256
 Vidaeff, A. C., 385
 Vreman, H. J., 85
 Wardle, S. P., 60
 Weindling, A. M., 60
 Weisoly, D., 426
 Wong, R. J., 85
 Yeh, T.-F., 94
 Yeung, C. Y., 50

Subject Index

- Abacavir for HIV-1-infected women and their newborn infants, 171, 175
 Abnormalities, *see* Congenital malformations; Fetal anomalies and malformations
 Abortion
 first-trimester, identification of, with three-dimensional US, 7-8
 induced, preterm labor and, 205, 210
 Absolute velocity of fetal DV blood flow, diagnostic uses of, 16
 ACE, *see* Angiotensin-converting enzyme inhibitors in pregnancy
 Acebutolol in pregnancy, 160
 ACSs, *see* Antenatal corticosteroids for fetal maturation; Antenatal corticosteroids for preterm labor and birth
 ACTH (adrenocorticotropic hormone), and HPA axis in premature infant, 372-373
 Acute asthma in pregnancy, pharmacological management of, 151
 Adenosine monophosphate, cyclic, PGE₂ receptor effects on production of, in fetal and neonatal DA, 72
 Adrenal hyperplasia, congenital, screening premature infants for, 379-380
 Adrenal steroids in premature infant, 373-375

- Adrenal suppression, neonatal, antenatal corticosteroids and, 387
- β -Adrenergic receptor agonists in pregnancy, *see* Beta-sympathomimetics in pregnancy
- α (alpha)-Adrenergic receptor antagonists in pregnancy, 130, 160, 162
- β (beta)-Adrenergic receptor antagonists in pregnancy, 130
- Adrenocorticotrophic hormone (ACTH), and HPA axis in premature infant, 372-373
- Adult cardiovascular system, PTHrP mRNA in, 79-80
- Adult kidney, PTHrP mRNA in, 79-80
- Adverse and beneficial effects of ACSs, 334-335, 342-345
- of multiple ACS courses, 343-345
 - of single ACS course, 342-343
- Adverse and beneficial effects of tocolytics, 316-340
- of atosiban, 333-334
 - of beta-sympathomimetics, 252-253, 322-325
 - see also* Calcium channel blockers, effects of; Magnesium sulfate, effects of; Prostaglandin synthetase inhibitor(s), effects of
- Adverse effects, *see* Fetal effects of drugs; Maternal effects of tocolysis; Neonatal effects of drugs in pregnancy; Safety and risks *and entries beginning with terms*: Adverse and beneficial effects
- AEDs, *see* Antiepilepsy drugs in pregnancy
- Age, maternal, preterm labor and, 205, 209-210
- Agensis, DV, three-dimensional and Doppler US of, 13-14
- Albumin binding capacity, and free bilirubin in neonatal jaundice, CE/FA in determination of, 50-54
- Alpha (α)-adrenergic receptor antagonists in pregnancy, 130, 160, 162
- Alternative approach(es) to preterm labor, 310-315
- bed rest as, 313
 - conclusions on, 314
 - HUAM as, 219-220, 310-311
 - hydration as, 313
 - long-term tocolysis as, 311-313
- Aminoglycosides in pregnancy, 139, 300
- Aminophylline in pregnancy, 151, 231
- Amnion, PTHrP in, 82
- Amobarbital in pregnancy, 156
- Ampicillin
- for infection-mediated preterm delivery, 295, 302-304
 - pregnancy effects on, 139
- Amrenavir in pregnancy, 171
- Anatomy
- fetal venous system, Doppler US of, 22-24
 - normal embryonic, three-dimensional US of, in early pregnancy, 3-4
- Anemia, maternal, preterm labor and, 205, 209-210
- Angiotensin-converting enzyme (ACE) inhibitors in pregnancy, 141, 162
- see also specific angiotensin-converting enzyme inhibitors*
- Angiotensin receptor blockers in pregnancy, 162
- Anomalies, *see* Malformations
- Antenatal antibiotics for infection-mediated preterm labor and birth, 229-230, 299-304, 311
- preventive role of, 299-301
 - and for PROM, 302-304
 - risks of widespread use of, 304
- Antenatal conditions and therapeutic interventions, *see* Fetus
- Antenatal corticosteroids (ACSs) for fetal maturation, 385-396
- dose and regimen of, 386-390
 - ideal form of, 391-392
 - ideal time for, 390
 - mechanism of action of, 392-393
- Antenatal corticosteroids (ACSs) for preterm labor and birth, 243, 318, 330, 334-335, 341-347
- adverse and beneficial effects of, *see* Adverse and beneficial effects of ACSs
 - history of, 341-342
 - long-term, 311
 - pharmacology and physiology of, 342
- Antenatal thyrotropin-releasing hormone (TRH) in prevention of neonatal lung disease, 406-416
- characteristics of trials with, 408-410
 - complications of, 412-413
 - discussion on, 414-415
 - effects of, on incidence of oxygen dependency or death and, *see* Incidence of oxygen dependency or death with antenatal TRH
 - effects of, on incidence of RDS, 410
 - effects of dose of, 413-414
- Anthracycline agents, placental transport of, 199
- Anti-asthma medications in pregnancy, 145-152
- current recommendations on use of, 150-151
 - effects of physiological changes of pregnancy on, 121-122
 - efficacy of, 146, 147
 - methodological considerations in study of, 146-147
 - newer, 149-150
 - and pregnancy outcome, 145-146
 - risks and safety of, 146-150
- Antibiotics
- pregnancy effects on, 115, 139, 142
 - see also* Antenatal antibiotics for infection-mediated preterm labor and birth *and specific antibiotics*
- Anticoagulants
- pregnancy effects on, 165-167
 - see also specific anticoagulants*
- Anticonvulsants, *see* Antiepilepsy drugs in pregnancy
- Antidepressants during pregnancy and lactation, 177-190
- depression and, *see* Depression
 - effects of physiological changes of pregnancy on metabolism of, 142
 - exposure to, defined, 178
 - introduction to, 115, 116
 - management issues with, during lactation, 184
 - management issues with, during pregnancy, 183-184
 - tricyclic, 116, 183

- Antiepilepsy drugs (AEDs; anticonvulsants) in pregnancy, 153-158
breast milk concentrations of, 156-157
changes in concentrations of, 154
and congenital malformations, 155-156
and effects of physiological changes of pregnancy on diseases, 139
fetal and neonatal effects of, 193-194
hormonal contraceptives and, 154
neonatal hemorrhage and, 156
see also specific antiepilepsy drugs
- Antihistamines in pregnancy, 122
- Antihypertensive drugs in pregnancy, 127, 128, 159-164
conclusions and recommendations on, 163
cost of, 159
effects of physiological changes in pregnancy on metabolism of, 122
goals of, 159-160
introduction to, 116
pharmacokinetics and pharmacodynamics of, 161-162
and pregnancy effects on specific diseases, 141
safety of, 162-163
see also specific antihypertensives
- Antiplatelet agents during pregnancy, 167
- Antiretroviral agents for HIV-1-infected women and their newborn infants, 170-176
intrapartum, 173-174
maternal pharmacokinetics of, and fetal risk with, 172-173
perinatal, 171-172
postnatal, for HIV-1-exposed neonates, 174-175
see also specific antiretroviral agents
- Antithrombotic therapy in pregnancy, 116, 165-169
with anticoagulants, 165-167
with antiplatelet agents, 167
- Apnea of prematurity, inhaled low (0.5%-1.5%) CO₂ for, 100-106
- L-Arginine, as tocolytic, 275
- Aspirin in pregnancy
low-dose, as anticoagulant, 167
as tocolytic, 230, 326, 328
- Assessment
of need for postnatal systemic steroids to prevent CLD in premature infants, 398
yolk sac, and identification of first-trimester pregnancy failure, 7-8
see also Risk(s) for preterm birth, assessment of and specific diagnostic techniques
- Asthma, *see* Anti-asthma medications in pregnancy
- Atenolol in pregnancy, 160, 163
- Atosiban, 231, 232, 332-335
clinical efficacy of, 333
fetal effects of, 333-334
indomethacin compared with, 326
long-term, 311-312
maternal effects of, 333
ritodrine and terbutaline compared with, 251, 333
 β -sympathomimetics compared with, 251, 333-335
- ATP (adenosine triphosphate)-dependent K⁺ (K_{ATP}) channels, 279-281
- Avermectin, placental transport of, 199
- Bacterial products in infection-mediated preterm labor and birth, 296
- Barbiturates, fetal and neonatal effects of, 191, 192
- Beclomethasone, inhaled, in pregnancy, 145, 150
- Bed rest for preterm labor, 313
- Bendectin in pregnancy, 119, 191
- Benefits, *see* Fetal effects of drugs; Maternal effects of tocolysis; Neonatal effects of drugs in pregnancy; Safety and risks and *entries beginning with terms*: Adverse and beneficial effects
- Beta (β)-adrenergic receptor antagonists in pregnancy, 130
- Betamethasone, 386, 387, 391
- Beta (β)-sympathomimetics (β -adrenergic receptor agonists), as tocolytics, 248-255, 330, 333-335
adverse and beneficial effects of, 252-253, 322-325
atosiban compared with, 251, 333-335
clinical efficacy of, 250, 252
indomethacin compared with, 251, 326
intravenous, 250
mechanism of action of, 248-249
MgSO₄ compared with, 241-243, 251
nifedipine compared with, 251
oral, 251
pharmacology of, 249-250
subcutaneous, 250-251
see also Ritodrine; Terbutaline, as tocolytic
- Beta (β)-sympathomimetics (β -adrenergic receptor agonists) in pregnancy
as anti-asthma drugs, 148, 150, 151
see also Beta-sympathomimetics, as tocolytics
- Betaxolol in pregnancy, 160
- Bilirubin (BR) in neonates
albumin binding capacity and free, in neonatal jaundice, CE/FA in determination of, 50-54
CO and production of, 85-93
- Binding proteins, *see* Insulin-like growth factor binding proteins in fetal growth and development
- Biological clock, *see* Circadian rhythms, fetal and neonatal development of
- Biological evidence of peroxide effects on total parenteral nutrition solutions, 56-57
- Biology, molecular, of PTH-rP, 76-77
- Biophase distribution of drugs in pregnancy, pharmacokinetics and pharmacodynamics of, 127-128
- Birth and delivery, *see* Preterm labor
- Blindness in extremely premature infants, 354-355
- Blood flow, *see* Circulation, fetal
- Blood lactate, peripheral FOE and whole, as measures of tissue oxygenation and guides to need for blood transfusions in premature infants, 60-64
- Blood shunting, *see* Umbilical venous blood shunting through fetal DV, three-dimensional US of

- Blood transfusions in premature infants, whole blood lactate and peripheral FOE, as measures of tissue oxygenation for, 60-64
- Bone formation, PTHrP in, 80-81
- BPs, *see* Insulin-like growth factor binding proteins in fetal growth and development
- BR, *see* Bilirubin in neonates
- Brain, *see* Fetal brain, transvaginal three-dimensional and Doppler US of; Neonatal brain and entries beginning with term: Neurodevelopmental
- Breast milk
AED concentrations in, 156-157
see also Lactation
- Budesonide, inhaled, in pregnancy, 150
- CAH (congenital adrenal hyperplasia), screening premature infants for, 379-380
- Calcium²⁺-activated K (K_{Ca}) channels, 279
- Calcium channel blockers (calcium antagonists), as tocolytics, 264-271, 334
effects of, *see* Calcium channel blockers, as tocolytics, effects of
long-term, 311, 312
mechanism of action of, 264-265
MgSO₄ compared with, 243-244
pharmacology of, 265
see also specific calcium channel blockers; for example:
Nifedipine, as tocolytic
- Calcium channel blockers (calcium antagonists), as tocolytics, effects of, 265-269, 316, 330-332
clinical efficacy of, 267-269, 330-331, 334, 335
fetal effects of, 265-266, 332
maternal effects of, 266-267, 331-332
- Calcium channel blockers (calcium antagonists) in pregnancy
as antihypertensives, 160, 162
see also Calcium channel blockers, as tocolytics
- Calcium gluconate, 269
- cAMP (cyclic adenosine monophosphate), PGE₂ receptor effects on production of, in fetal and neonatal DA, 72
- Capillary electrophoresis (CE) with FA in determination of albumin binding capacity and free bilirubin in neonatal jaundice, 50-54
- Carbamazepine in pregnancy, 154-157, 192
- Carbohydrate metabolism changes in pregnancy, effects of, on diseases, 142
- Carbon dioxide (CO₂), inhaled low (0.5%-1.5%), for apnea of prematurity, 100-106
- Carbon monoxide (CO), and neonatal bilirubin production, 85-93
- Cardiovascular changes in pregnancy, effects of, on diseases, 140-141
- Cardiovascular effects of beta-sympathomimetics, 253, 324
- Cardiovascular system, adult, PTHrP in, 79-80
- Case-control studies of anti-asthma medications during pregnancy, 147
- Catecholamine-resistant hypotension in premature infants, dexamethasone for, 379
- CE (capillary electrophoresis) with FA in determination of albumin binding capacity and free bilirubin in neonatal jaundice, 50-54
- Ceftizoxime in infection-mediated preterm delivery, 302
- Central nervous system, *see* Fetal brain, transvaginal three-dimensional and Doppler US of; Neonatal brain and entries beginning with term: Neurodevelopmental
- Cephalosporins in infection-mediated preterm delivery, 301
- Cerebral palsy (CP), neonatal
fetal infections, preterm labor and, 282-286
prevalence of, in extremely premature infant, 354
- Cerebroprotective effects on neonatal brain of IGFs, 432
of MgSO₄, 317-318, 321-322
- Cervical length, as risk for preterm labor and birth, 216-217
- Cervical ripening inhibitors, preterm labor management with, 281-282
- Cervical surgery, preterm labor and, 205, 207-208
- Chorioamnionitis, preterm labor and birth and, 297
- Chromosomally abnormal 11-to-14-week old fetus, Doppler US of, 32-37
- Chronic asthma, pregnancy with, recommendations for pharmacological management of, 150
- Chronic hypertension in pregnancy, *see* Hypertensive disorders in pregnancy
- Chronic lung disease, *see* Postnatal steroids to prevent CLD in premature infants
- Cigarette smoking, maternal, preterm labor and, 205, 208
- Circadian rhythms, fetal and neonatal development of, 363-370
conclusions on, 368
described, 365-367
SCN and, *see* Suprachiasmatic nucleus, fetal
- Circulating insulin-like growth factor(s) (IGF) in fetal growth and development, 429
- Circulation, fetal
of brain, three-dimensional sono-angiography of, 40-41; *see also* Fetal brain, transvaginal three-dimensional and Doppler US of
historical background to, 21-22
see also Ductus venosus, fetal, three-dimensional and Doppler US of blood flow velocity in
- Citalopram during pregnancy and lactation, 184
- Clavulanic acid in infection-mediated preterm delivery, 303
- CLD (chronic lung disease), *see* Postnatal steroids to prevent CLD in premature infants
- Clindamycin, 121, 300, 302, 303
- Clinical efficacy
of anti-asthma medications, 146, 147
of antihypertensive drugs, 160-161
of atosiban, 333
of beta-sympathomimetics, 250, 252
of calcium channel blockers, 267-269, 330-331
of COX-2 inhibitors, 260
of MgSO₄, 240-245, 317
of prostaglandin synthetase inhibitors, 257, 326

- Clinical evidence, 180-182
 for depression impact during pregnancy, 180-181
 for PPD impact during pregnancy, 181-182
Clinical implications of Doppler US evaluation of fetal venous system, 30
Clinical outcome, *see* Outcome
Clonidine in pregnancy, 160
CNS (central nervous system), *see* Fetal brain, transvaginal three-dimensional and Doppler US of; Neonatal brain *and entries beginning with term*: Neurodevelopmental
CO (carbon monoxide), and neonatal bilirubin production, 85-93
CO₂ (carbon dioxide), inhaled low (0.5%-1.5%), for apnea of prematurity, 100-106
Cohort studies of anti-asthma medications in pregnancy, 147
Colchicine, placental transport of, 199
Complications, *see* Fetal effects of drugs; Maternal effects of tocolysis; Neonatal effects of drugs in pregnancy; Safety and risks *and entries beginning with terms*: Adverse and beneficial effects
Concentrations, drug
 of AEDs in pregnancy and lactation, 154
 of zidovudine in cord blood, 174
Conception, interval duration between menstruation and, and preterm labor, 205, 210
Congenital adrenal hyperplasia (CAH), screening premature infants for, 379-380
Congenital malformations
 due to AEDs, 154
 due to anti-asthma medications, 148-150
 see also Fetal anomalies and malformations
Convulsions, *see* Antiepilepsy drugs in pregnancy
Cord blood
 serum binding capacity of, for bilirubin in neonatal jaundice, 51
 zidovudine concentrations in, 174
Corticosteroids, *see* Corticosteroids in pregnancy; Fetal and neonatal hormonal therapy *and entries beginning with terms*: Antenatal corticosteroids
Corticosteroids in pregnancy
 inhaled, 115, 116, 145, 147-150
 parenteral and intravenous, 151
 and pregnancy effects on specific diseases, 142
 systemic, 116, 145, 147, 149, 150
Corticotropin-releasing hormone (CRH), and HPA axis in premature infant, 371-372
Cortisone in pregnancy, 194
Cost of antihypertensive therapy in pregnancy, 159
Coumarin in pregnancy, 141
COX-2 inhibitors, *see* Cyclooxygenase-2 inhibitors
CP, *see* Cerebral palsy, neonatal
CRH (corticotropin-releasing hormone), and HPA axis in premature infant, 371-372
Cromolyn, inhaled, in pregnancy, 145, 148-150
Cyclic adenosine monophosphate (cAMP), PGE₂ receptor effects on production of, in fetal and neonatal DA, 72
Cyclooxygenase-2 (COX-2) inhibitors, 257, 259-261, 273, 281
 adverse effects of, 260-261
 pharmacology and clinical efficacy of, 260
Cyclosporine, placental transport of, 199
Cytokines, role of, in infection-mediated preterm labor and birth, 296-297
DA (ductus arteriosus), fetal and neonatal, PGE₂ receptors in, 70-75
Dalteparin in pregnancy, 166
Deafness in extremely premature infants, 355
Delavirdine for HIV-1-infected women and their newborn infants, 171
Depression, 178-180
 impact of, during pregnancy, 180-181
 perinatal, incidence and phenomenology of, 178-180
 postpartum, *see* Postpartum depression
 see also Antidepressants during pregnancy and lactation
Development, *see* Antenatal corticosteroids for fetal maturation; Circadian rhythms, fetal and neonatal development of; Embryonic growth and development; Fetal growth and development; Mental development *and entries beginning with term*: Neurodevelopmental
Dexamethasone
 postnatal, in premature infants, 378-379
 see also Dexamethasone in pregnancy; Fetal dexamethasone
Dexamethasone in pregnancy
 effects of, on postnatal endothelial nitric oxide synthase, 94-99
 pregnancy effects on, 129
Dextromorphan in pregnancy, 121
Diabetes, neonatal, insulin homeostasis and, 441
Diameter, ductus arteriosus, PGE₂ receptor effects on, 72-73
Diazepam in pregnancy, 156
Diazoxide, 231
Didanosine for HIV-1-infected women and their newborn infants, 171
Diethylstilbestrol, 191
Digoxin, 141
 transplacental therapy of fetal tachycardia with, 196-200
Diltiazem, 265, 267, 269
Dimensions of DV, three-dimensional and Doppler US of, 14
Direct drug effects, simple reversible, in pregnancy, pharmacokinetics and pharmacodynamics of, 125-127
Direct exposure to antidepressants, defined, 178
Disabilities in extremely premature infants, prevalence of, 355-356
Disposition of drugs in pregnancy, *see* Drug(s) in pregnancy
Diuretics in pregnancy, 141, 160, 162
 see also specific diuretics
Donohue's syndrome (leprechaunism), and defective signal insulin transduction, 431

- Doppler ultrasound, *see* Three-dimensional and Doppler ultrasound
- Dose
- antenatal TRH, effects of, 413-414
 - fetal corticosteroid, for fetal maturation, 386-390
 - low aspirin, as anticoagulant, 167
 - MgSO₄, 237, 238
- Drug administration, *see* entries beginning with terms:
- Inhaled, Intravenous, Parenteral, Subcutaneous, Systemic
- Drug(s) in pregnancy
- introduction to, 115-119
 - stable isotopes in studies of, 133-138
 - see also* Antenatal antibiotics for infection-mediated preterm labor and birth; Antenatal corticosteroids for fetal maturation; Antenatal corticosteroids for preterm labor and birth; Anti-asthma medications in pregnancy; Antidepressants during pregnancy and lactation; Antiepilepsy drugs in pregnancy; Antiretroviral agents for HIV-1-infected women and their newborn infants; Antithrombotic therapy in pregnancy; Corticosteroids in pregnancy; Hypertensive disorders in pregnancy; Pharmacokinetics and pharmacodynamics in pregnancy; Physiological changes in pregnancy, effects of; Tocolysis; Transplacental therapy of fetal tachycardia and entries beginning with terms: Adverse and beneficial effects
- Drug resistance, multiresistance 1-type P glycoprotein in placental drug transport, 199
- Drug transport, *see* Placental drug transport and specific drugs
- Ductus arteriosus (DA), fetal and neonatal, PGE₂ receptors in, 70-75
- Ductus venosus (DV)
- neonatal, three-dimensional and Doppler US of, 17
 - see also* Ductus venosus, fetal, three-dimensional and Doppler US of
- Ductus venosus (DV), fetal, three-dimensional and Doppler US of blood flow velocity in
- absolute blood flow velocity, 16
 - in chromosomally abnormal 11-to-14-week old fetus, 34
 - pulsatile blood flow velocity, 14-16
- Ductus venosus (DV), fetal, three-dimensional and Doppler US of, 11-20, 26-29
- of blood flow velocity, *see* Ductus venosus, fetal, three-dimensional and Doppler US of blood flow velocity in
 - of blood shunting through DV, *see* Umbilical venous blood shunting through fetal DV, three-dimensional US of
 - in chromosomally abnormal 11-to-14-week old fetus, 32-37
 - of DV agenesis, 13-14
 - of physical properties, 14
 - waveform analysis of, 16-17
- DV, *see* Ductus venosus
- Early onset group B streptococcus infection (EOGBS), guidelines on prevention of, 107-113
- Early postnatal life, function of insulin in, 436-439
- Early pregnancy, three-dimensional US in, 3-10
- of fetal malformation diagnosis, 5-6
 - of normal embryonic growth and anatomy, 3-4
 - for nuchal translucency measurement, 6-7
 - safety of, 8-9
 - for yolk sac assessment and identification of first-trimester pregnancy failure, 7-8
- Echography, *see* Three-dimensional and Doppler ultrasound
- Efavirenz for HIV-1-infected women and their newborn infants, 171
- Efficacy, *see* Clinical efficacy
- Electrophoresis, FA with capillary, in determination of albumin binding capacity and free bilirubin in neonatal jaundice, 50-54
- 11-to-14-week old fetus, chromosomally abnormal, Doppler US of, 32-37
- Embryonic growth and development
- of kidney, PTHrP mRNA in, 78-79
 - normal anatomy and normal, in early pregnancy, three-dimensional US of, 3-4
- Employment, maternal, preterm labor and, 205, 209
- Endocrine control of term labor onset, 224-226
- Endometritis, preterm birth and, 297
- Endothelial nitric oxide synthase (eNOS), postnatal, effects of antenatal dexamethasone on, 94-99
- Enoxaparin in pregnancy, 166
- Entrainment signals entering fetal SCN, 367-368
- EOGBS (early onset group B streptococcus infection), implementation of guidelines on prevention of, 107-113
- EP₂, EP₃, and EP₄ receptors of PGE₂ in fetal and newborn ductus arteriosus, 70-75
- Epidemiology of preterm labor, 204-214
- cervical surgery in, 205, 207-208
 - induced abortion in, 205, 210
 - interpregnancy interval in, 205, 208-209
 - maternal anemia and maternal age in, 205, 209-210
 - maternal cigarette smoking and substance abuse in, 205, 208
 - maternal periodontal disease and prolonged menstruation-conception interval in, 205, 210
 - maternal work and employment and socioeconomic status in, 205, 209
 - multifetal gestation in, 205, 207
 - potential paternal risk factors in, 211
 - prior history of preterm labor in, 205
 - race in, 205, 206
 - reproductive tract infections in, *see* Reproductive tract infections, preterm labor and birth and uterine malformations in, 205, 208
- Epilepsy, *see* Antiepilepsy drugs in pregnancy
- Equipment used in CE/FA, 50-51
- Erythromycin for infection-mediated preterm delivery, 295, 300-303
- Estriol, salivary, in preterm labor risk assessment, 205, 218-219

- Ethanol, as tocolytic, 231, 312, 326
- Ethosuximide in pregnancy, 154, 156, 157
- Excretion, urinary peroxide, effects of
 photoprotection of total parenteral nutrition
 solutions on infused total parenteral
 nutrition load and, in premature infants, 55-
 59
- Expectant management of preterm labor, 282-287
 due to fetal growth anomalies, 286-287
 due to fetal infections, 282-286
- Exposure
 to antidepressants during pregnancy and
 lactation, defined, 178
 neonatal, to HIV infection, postnatal antiretroviral
 agents for, 174-175
 see also Drug(s) in pregnancy
- Extremely premature infants, *see* Insulin therapy in
 extremely premature infants; Outcome of
 extremely premature infants; Postnatal
 thyroid hormone replacement in extremely
 premature infants
- FA (frontal analysis), CE and, in determination of
 albumin binding capacity and free bilirubin
 in neonatal jaundice, 50-54
- Failure of pregnancy, early, three-dimensional US
 identification of, 7-8
- Felbamate in pregnancy, 154, 156, 157
- Female fetus, 21- or 11-hydroxylase-deficient
 premature, dexamethasone in prevention of
 virilization of, 379
- Fenoprofen, 230
- Fetal anomalies and malformations
 Doppler US of chromosomally abnormal 11-to-14-
 week old fetus, 32-37
 and preterm labor, 286-287
 three-dimensional US of, in early pregnancy, 5-6
 see also Congenital malformations; Fetal effects of
 drugs and specific malformations
- Fetal brain, transvaginal three-dimensional and
 Doppler US of, 38-43
 structure of, *see* Structure, fetal brain, three-
 dimensional and Doppler US of
 and surface imaging of fetal head, 39-40
 three-dimensional sono-angiography of fetal brain
 circulation, 40-41
- Fetal circulation, *see* Circulation, fetal
- Fetal dexamethasone
 HPA axis and, 377-378
 to induce maturation, 387, 391, 392
 to prevent virilization in 21- or 11-hydroxylase
 deficiency in female fetus, 379
- Fetal diagnosis, *see* Three-dimensional and Doppler
 ultrasound and specific conditions
- Fetal ductus arteriosus (DA), PGE₂ receptors in, 70-
 75
- Fetal ductus venosus, *see* Ductus venosus, fetal,
 three-dimensional and Doppler US of
- Fetal effects of drugs, 191-195
 of TRH to prevent CLD, 412-413
 see also Fetal effects of tocolysis; Safety and risks of
 drug therapy in pregnancy
- Fetal effects of tocolysis
 of atosiban, 333-334
 of beta-sympathomimetics, 325
 of calcium channel blockers, 265-266, 332
 of MgSO₄, 318-321
 of prostaglandin synthetase inhibitors, 327-330
- Fetal fibronectin, preterm labor risk assessment
 with, 205, 217-218
- Fetal growth and development
 ACS effects on, 344
 anomalies of, and preterm labor, 286-287
 see also Antenatal corticosteroids for fetal
 maturation; Circadian rhythms, fetal and
 neonatal development of; Fetal growth and
 development, regulatory function of insulin
 and IGFs in; Fetal lung development;
 Parathyroid hormone-related protein, role of,
 in development
- Fetal growth and development, regulatory function
 of insulin and IGFs in, 426-435
 and of GH and related peptides and, 426-427
 of IGFs, *see* Insulin-like growth factor(s), fetal
 growth and development and
 of insulin, *see* Insulin in fetal growth and
 development
- Fetal head surface, Doppler US of, 39
- Fetal Hydantoin Syndrome, 191, 193
- Fetal infections, preterm labor and birth and, 297-
 298
 neonatal cerebral palsy and, 282-286
- Fetal intracranial structure, multiplanar imaging of,
 39-40
- Fetal kidney, PTHrP mRNA in developing, 78-79
- Fetal life
 function of insulin in, 436-439
 intracellular T3 availability during, 418-419
 thyroid hormone production and metabolism
 during, 417-418
- Fetal lung development
 ACS effects on, 343-344
 dexamethasone effects on, 94-99
 PTHrP in, 82
- Fetal malformations, *see* Fetal anomalies and
 malformations
- Fetal and neonatal hormonal therapy
 introduction to, 361-362
 see also Antenatal thyrotropin-releasing hormone
 in prevention of neonatal lung disease;
 Circadian rhythms, fetal and neonatal
 development of; Fetal growth and
 development, regulatory function of insulin
 and IGFs in; Hypothalamic-pituitary-adrenal
 axis in premature infants; Insulin therapy in
 extremely premature infants; Postnatal
 steroids to prevent CLD in premature infants;
 Postnatal thyroid hormone replacement in
 extremely premature infants and entries
 beginning with terms: Antenatal corticosteroids
- Fetal tachycardia, *see* Transplacental therapy of fetal
 tachycardia
- Fetal Trimethadione Syndrome, 193

- Fetal umbilical artery, *see* Umbilical artery, fetal, Doppler velocimetry of
- Fetal umbilical vein, *see* Umbilical vein, fetal
- Fetal vena cava, inferior, Doppler US of, 25-26
- Fetal venous system, Doppler US of, 21-31
 anatomy of, 22-24
 clinical implications of, 30
 of DV, *see* Ductus venosus, fetal, three-dimensional and Doppler US of
 historical background of fetal circulation, 21-22
 and history of Doppler US, 22-23
 of inferior vena cava, 25-26
 umbilical vein, 22-23
- "Fetal warfarin syndrome", 141
- Fetus
 21- or 11-hydroxylase-deficient premature female, dexamethasone in prevention of virilization of, 379
see also entries beginning with terms: Antenatal, Fetal
- Fibronectin, fetal, in preterm labor risk assessment, 205, 217-218
- First trimester, *see* Early pregnancy, three-dimensional US in
- Flecainide, transplacental therapy with, 197
- Fluid dynamics in fetal DV, three-dimensional and Doppler US of, 14
- Fluoxetine during pregnancy and lactation, 183, 184
- Fluvoxamine during pregnancy and lactation, 183, 184
- Fractional oxygen extraction (FOE), whole blood lactate and peripheral, as measures of tissue oxygenation and guide to need for blood transfusions in premature infants, 60-64
- Free bilirubin, albumin binding capacity and, in neonatal jaundice, CE/FA in determination of, 50-54
- Frequency of seizures, pregnancy effects on, 154
- Furosemide in pregnancy, 160
- Gabapentine in pregnancy, 157
- Gastrointestinal changes in pregnancy, effects of, on diseases, 143
- Gastrointestinal effects, maternal, of beta-sympathomimetics, 324
- GBS, *see* Group B streptococcus infection
- Gene disruption, IFG-I, IGF-1R, IGF-2R, in fetal growth and development, 430-431
- Gene expression, *see* mRNA
- Generation of peroxides in total parenteral nutrition solutions, 55-56
- Genital tract infections, *see* Reproductive tract infections, preterm labor and birth and
- Genomic imprinting, IGF-II gene expression in fetal growth and development and, 430
- Gentamicin, 121-122, 139, 303
- GH (growth hormone), role of, in fetal growth and development, 426-427
- Glucocorticoids, *see* Fetal and neonatal hormonal therapy and specific glucocorticoids
- Glucose tolerance in extremely premature infants, insulin therapy enhancing, 441-443
- Glyceril trinitrate, 275-277
- P-Glycoprotein, digoxin transport by, 198-200
- Goals of antihypertensive therapy in pregnancy, 159-160
- Group B streptococcus (*Streptococcus agalactiae*, GBS) infection
 early onset, implementation of guidelines on prevention of, 107-113
 and ibuprofen regulation of iNOS mRNA by blocking NF κ B activation, 65-69
- Growth and development, *see* Embryonic growth and development; Fetal growth and development; Mental development and entries beginning with term: Neurodevelopmental
- Growth hormone (GH), role of, in fetal growth and development, 426-427
- Guidelines
 on EOGBS prevention, implementation of, 107-113
see also Recommendations on drug therapy in pregnancy
- Hair, PTHrP in development of, 81-82
- Head surface, fetal, Doppler US of, 39
- Hematologic changes in pregnancy, effects of, on diseases, 139-140
- Hemorrhage, neonatal, and AED therapy in pregnancy, 156
- Heparin in pregnancy, 166-167
 introduction to, 116-117
 low-dose aspirin with, 167
 low molecular weight, 166-167
 pharmacokinetics and pharmacodynamics of simple reversible direct effects of, 125-126
 unfractionated, 166
- High-risk pregnancies, umbilical artery Doppler velocimetry in, 45-46
- History
 of ACSs, 341-342
 of Doppler US, 22-23
 historical background of fetal circulation, 21-22
 historical perspective on term labor onset, 223-224
 of MgSO₄, 236-237
 prior preterm labor, preterm labor and, 205
- HIV-1 infection, *see* Antiretroviral agents for HIV-1-infected women and their newborn infants
- Home uterine activity monitoring (HUAM) for preterm labor, 219-220, 310-311
- Homeostasis, insulin, *see* Insulin therapy in extremely premature infants
- Hormonal contraceptives, AEDs and, 154
- Hormonal therapy, *see* Fetal and neonatal hormonal therapy
- HPA axis, *see* Hypothalamic-pituitary-adrenal axis in premature infant
- HUAM (home uterine activity monitoring) for preterm labor, 219-220, 310-311

- Human immunodeficiency virus-1 infection, *see*
Antiretroviral agents for HIV-1-infected
women and their newborn infants
- Hydantoin in pregnancy, 191, 193
- Hydralazine in pregnancy, 160-162
- Hydration for preterm labor, 313
- 21- or 11-Hydroxylase-deficient premature female
fetus, dexamethasone in prevention of
virilization in, 379
- Hyperbilirubinemia, *see* Bilirubin in neonates
- Hyperglycemia in extremely premature infant,
prevention of, with insulin therapy, 439-440
- Hyperplasia, congenital adrenal, screening
premature infants for, 379-380
- Hyperreactivity, uterine muscle, 146
- Hypertensive disorders in pregnancy, 159-164
clinical significance of, 159
management of, *see* Antihypertensive drugs in
pregnancy
- Hypotension, catecholamine-resistant, in premature
infants, dexamethasone for, 379
- Hypothalamic-pituitary-adrenal (HPA) axis in
premature infants, 371-384
ACTH and, 372-373
adrenal steroids and, 373-375
CRH and, 371-372
dexamethasone therapy and, 378-379
in 24- to 30-week premature infant, 375-377
- Hypothyroxinemia, *see* Postnatal thyroid hormone
replacement in extremely premature infants
- Ibuprofen, 65-69, 326
- Ideal form of fetal corticosteroids for fetal
maturation, 391-392
- Ideal time for fetal corticosteroids for fetal
maturation, 390
- Idiopathic preterm labor (uterine muscle
hyperreactivity), 146
- IGFs, *see* Insulin-like growth factor(s)
- Implementation of guidelines on EOGBS
prevention, 107-113
- Imprinting, genomic, IFG-II gene expression in fetal
growth and development and, 430
- Incidence
of perinatal depression, 180-181
of RDS, antenatal TRH effects on, 410
see also Incidence of oxygen dependency or death
with antenatal TRH; Prevalence and specific
conditions
- Incidence of oxygen dependency or death with
antenatal TRH, 410-412
at 28 days after birth, 410-411
at 26 weeks after birth, 411-412
- Indications
for antihypertensive therapy in pregnancy, 160
see also specific conditions
- Indinavir in pregnancy, 171, 172
- Indirect drug effects in pregnancy, 128-130
- Indirect exposure to antidepressants, defined, 178
- Indomethacin, as tocolytic, 230
atosiban compared with, 326
adverse and beneficial effects of, 258-259, 325-330
clinical efficacy of, 257
COX-2 inhibitors compared with, 281
MgSO₄ compared with, 243, 244, 319, 321
 β -sympathomimetics compared with, 251, 326
terbutaline and ritodrine compared with, 251
- Indomethacin in pregnancy
fetal and neonatal effects of, 192
see also Indomethacin, as tocolytic
- Induced abortion, preterm labor and, 205, 210
- Inducible nitric oxide synthase (iNOS) mRNA,
effects of GBS infection and ibuprofen
blockage of NF κ B activation on, 65-69
- Infections, *see* Preterm birth, infection-mediated
- Inferior vena cava, fetal, Doppler US of, 25-26
- Infused load of total parenteral nutrition solutions,
effects of photoprotection on urinary
excretion of peroxides and, in premature
infants, 55-59
- Inhaled β (beta)-sympathomimetics for asthma in
pregnancy, 150, 151
- Inhaled beclomethasone in pregnancy, 145, 150
- Inhaled budesonide for asthma in pregnancy, 150
- Inhaled cromolyn in pregnancy, 145, 148-150
- Inhaled low (0.5%-1.5%) carbon dioxide (CO₂) for
apnea of prematurity, 100-106
- Inhaled metaproterenol in pregnancy, 150
- Inhaled nedocromyl in pregnancy, 150
- Inhaled salmeterol in pregnancy, 150
- Inhaled steroids
postnatal, to prevent CLD in premature infants,
403
in pregnancy, 115, 116, 145, 147-150
- Inhaled theophylline in pregnancy, 145, 148, 151
- iNOS (inducible nitric oxide synthase) mRNA
(messenger ribonucleic acid), effects of GBS
infection and ibuprofen blockage of NF κ B
activation on, 65-69
- Insulin, *see* Insulin in fetal growth and development;
Insulin therapy in extremely premature
infants
- Insulin in fetal growth and development
effects of defective signal transduction on, 431
and insulin function in fetal life, 436-439
role of, 427
see also Insulin-like growth factor(s), fetal growth
and development and
- Insulin-like growth factor(s) (IGF)
in perinatal period, 432
see also Insulin-like growth factor(s), fetal growth
and development and
- Insulin-like growth factor(s) (IGF), fetal growth and
development and, 427-431
circulating forms of, 429
effects of defective signal transduction, 431
evidence for, 429-430
regulatory function of, 427-428
see also entries beginning with terms: Insulin-like
growth factor
- Insulin-like growth factor binding proteins (BP) in
fetal growth and development
effects of abnormal gene expression of, 431
role of, 428-429

- Insulin-like growth factor receptors (IGF-R) in fetal growth and development, 428
- Insulin-like growth factor-I (IGF-I) gene disruption in fetal growth and development, 430-431
- Insulin-like growth factor-I receptor (IGF-IR) gene disruption in fetal growth and development, 430-431
- Insulin-like growth factor-II (IGF-II) gene expression in fetal growth and development, genomic imprinting and, 430
- Insulin-like growth factor-2 receptor (IGF-2R) gene disruption in fetal growth and development, 431
- Insulin therapy in extremely premature infants, 463-446
to enhance glucose tolerance, 441-443
and function of insulin in fetal and early postnatal life, 436-439
for neonatal diabetes, 441
in prevention of hyperglycemia, 439-440
safety and risks, 443-444
- Interpregnancy interval, preterm labor and, 205, 208-209
- Intracellular triiodothyronine (T3) availability during fetal life, 418-419
- Intracranial structure, multiplanar fetal, three-dimensional and Doppler US of, 39-40
- Intrapartum antiretroviral drugs for HIV-1-infected pregnant women and their newborn infants, 173-174
- Intrapartum umbilical artery Doppler velocimetry, 46
- Intravenous aminophylline in pregnancy, 151
- Intravenous beta (β)-sympathomimetics, 250
- Intravenous methylprednisolone in pregnancy, 151
- Intravenous steroids in pregnancy, 151
- Ipratropium in pregnancy, 150, 151
- Isotopes, stable, used in studies of drug metabolism in pregnancy, 133-138
- Isotretinoin in pregnancy, 192
- Isoxsuprine, 230
- Isradipine in pregnancy, 160
- Jaundice, neonatal, CE/FA in determination of albumin binding capacity and free bilirubin in, 50-54
- K⁺ (potassium ion) channel openers in preterm labor, 231, 278-281
- Ketanserin in pregnancy, 160, 161
- Ketorolac, 243, 244
- Kidney, PTHrP expression in, 78-80
in adult kidney, 79-80
in fetal and/or embryonic kidney, 78-79
- Labetalol in pregnancy, 130-131, 160, 161
- Labor, *see* Preterm labor
- Laboratory conditions for CE/FA of albumin binding capacity and free bilirubin in neonatal jaundice, 51
- Lactate, peripheral FOE and whole blood, as measures of tissue oxygenation and guides to need for blood transfusions in premature infants, 60-64
- Lactation
and breast milk concentrations of AEDs, 156-157
PTHrP role in, 81
see also Antidepressants during pregnancy and lactation
- Lamivudine for HIV-1-infected pregnant women and their newborn infants, 171, 172
- Lamotrigine in pregnancy, 156, 157
- Length of cervix, as risk for preterm birth, 216-217
- Leprechaunism (Donohue's syndrome), and defective signal insulin transduction, 431
- Levcromakalin, 231, 280
- Levetiracetam in pregnancy, 156, 157
- LMWH (low molecular weight heparin) in pregnancy, 166-167
- Long-term tocolysis in preterm labor management, 311-313
- Lopinavir/Ritonavir for HIV-1-infected pregnant women and their newborn infants, 171
- Low (0.5%-1.5%) carbon dioxide (CO₂), inhaled, for apnea of prematurity, 100-106
- Low-dose aspirin in pregnancy, 167
- Low molecular weight heparin (LMWH) in pregnancy, 166-167
- Low-risk pregnancies, umbilical artery Doppler velocimetry in, 46
- Lower reproductive tract infections, preterm birth and, 298-299
- Lung(s), *see* Fetal lung development
- Lung disease, *see* Antenatal thyrotropin-releasing hormone in prevention of neonatal lung disease; Postnatal steroids to prevent CLD in premature infants
- Magnesium sulfate (MgSO₄), 236-238, 267-269
adverse and beneficial effects of, *see* Magnesium sulfate, effects of
history of, 236-237
indomethacin compared with, 243, 244, 319, 321
long-term, 311, 312
nifedipine and, 243, 244, 269, 276, 319, 321, 330, 331
pharmacokinetics of, 237-238
research on, 322
ritodrine compared with, 242-243, 319, 321
 β -sympathomimetics compared with, 241-243, 251
terbutaline compared with, 241-243, 251, 319, 321
- Magnesium sulfate (MgSO₄), effects of, 230, 232, 317-322, 334, 335
clinical efficacy, 240-245, 317
fetal effects, 318-321
maternal effects, 238-239, 318, 331-332
neonatal effects, 239-240, 325
protective effects of, on neonatal brain, 317-318, 321-322
- Malformations
uterine, preterm labor and, 205, 208
see also Congenital malformations; Fetal anomalies and malformations
- Mammary gland, PTHrP in development of, 81

- Maternal age, preterm labor and, 205, 209-210
Maternal anemia, preterm labor and, 205, 209-210
Maternal cigarette smoking, preterm labor and, 205, 208
Maternal drug therapy, *see* Drug(s) in pregnancy;
Maternal effects of tocolysis
Maternal effects of tocolysis
with atosiban, 333
with beta-sympathomimetics, 324
with calcium channel blockers, 266-267, 331-332
with MgSO_4 , 238-239, 318, 331-332
with prostaglandin synthetase inhibitors, 327
Maternal group B streptococcus carriers
(*Streptococcus agalactiae*), and guidelines to
prevent EGBS, 107-113
Maternal infections, *see* Reproductive tract
infections, preterm labor and birth and
Maternal periodontal disease, preterm labor and,
205, 210
Maternal pharmacodynamics
of antiretroviral agents, fetal risk and, 172-173
see also Pharmacokinetics and pharmacodynamics
in pregnancy
Maternal socioeconomic status, preterm labor and,
205, 209
Maternal substance abuse, preterm labor and, 205,
208
Maternal work and employment, preterm labor and,
205, 209
Maturation, *see* Antenatal corticosteroids for fetal
maturation; Embryonic growth and
development; Fetal lung development;
Mental development and entries beginning with
term; Neurodevelopmental
MDR1 (multidrug resistance 1)-type P-glycoprotein
in placental drug transport, 199
Mechanism of action
of beta-sympathomimetics, 248-249
of calcium channel blockers, 264-265
of fetal corticosteroids, 392-393
of MgSO_4 , 237
of PTHrP, 77-78
Meloxicam, 230
Menstruation-conception interval, preterm labor
and, 205, 210
Mental development, extreme prematurity and
impaired, 353-354
Mephenytoin, fetal and neonatal effects of, 193
Mephobarbital in pregnancy, 156
Metabolic effects of beta-sympathomimetics, 324,
353
Metabolism
drug, *see* Drug(s) in pregnancy
thyroid hormone production and, 417-418
Metaproterenol, inhaled, in pregnancy, 150
Methyldopa in pregnancy, 113, 160, 162-163
Methylprednisolone, intravenous, in pregnancy, 151
Metoprolol in pregnancy, 160
Metronidazole for infection-mediated preterm
delivery, 295, 300-302
Mezlocillin for infection-mediated preterm delivery,
302, 303
 MgSO_4 , *see* Magnesium sulfate
Molecular biology of PTHrP, 76-77
Montelukast in pregnancy, 150
Mortality
due to MgSO_4 , 320
of extremely premature infant, prediction of, 351
see also Incidence of oxygen dependency or death
with antenatal TRH
mRNA (messenger ribonucleic acid)
IGF binding protein, effects of abnormal, 431
IGF-II, in fetal growth and development, genomic
imprinting and, 430
iNOS, effects of GBS infection and ibuprofen
blockage of NF κ B activation on, 65-69
see also mRNA, PTHrP
mRNA (messenger ribonucleic acid), PTHrP, 78-81
in adult cardiovascular system, 79-80
during embryonic and fetal development, 78
in kidney, *see* Kidney, PTHrP expression in
in placenta, 81
Multidrug resistance 1 (MDR1)-type P-glycoprotein
in placental drug transport, 199
Multifetal gestation
antenatal corticosteroid dose and regimen in, 389
preterm labor and, 205, 207
Multiplanar intracranial structure, fetal, three-
dimensional and Doppler US of, 39-40
Multiple fetal corticosteroid courses, adverse and
beneficial effects of, 343-345

L-NAME (L-nitro-arginine methyl ester), 281
Naproxen in pregnancy, 230, 326
Narcotics in pregnancy, 191
Nedocromil, inhaled, in pregnancy, 150
Nelfinavir for HIV-1-infected pregnant women and
their newborn infants, 171
Neonatal adrenal suppression, antenatal
corticosteroids and, 387
Neonatal antiretroviral therapy, *see* Antiretroviral
agents for HIV-1-infected women and their
newborn infants
Neonatal brain
IGFs in development and protection of, 432
protective effects on, *see* Cerebroprotective effects
on neonatal brain
see also Cerebral palsy, neonatal;
Neurodevelopmental outcome, neonatal
Neonatal diabetes, insulin therapy of, 441
Neonatal ductus arteriosus (DA), PGE $_2$ receptors in,
70-75
Neonatal ductus venosus (DV), three-dimensional
and Doppler US of, 17
Neonatal effects of drugs in pregnancy, 191-195
of AEDs, hemorrhages as, 156
see also Neonatal effects of tocolytics; Safety and
risks of drug therapy in pregnancy and specific
drugs
Neonatal effects of tocolytics, 325
of MgSO_4 , 239-240, 317-318, 321-322
of β -sympathomimetics, 252

- Neonatal growth and development
 IGFs in, 432
see also Circadian rhythms, fetal and neonatal development of and specific conditions
- Neonatal hemorrhages, and AED therapy in pregnancy, 156
- Neonatal hormonal therapy, *see* Fetal and neonatal hormonal therapy
- Neonatal hyperbilirubinemia, *see* Bilirubin in neonates
- Neonatal jaundice, CE/FA in determination of albumin binding capacity and free bilirubin in, 50-54
- Neonatal lung disease, *see* Antenatal thyrotropin-releasing hormone in prevention of neonatal lung disease; Postnatal steroids to prevent CLD in premature infants
- Neonatal nutrition, IGFs in, 432
- Neonatal outcome
 beta-sympathomimetic effects on, 252
 effects of hypothyroxinemia on, 420-421
 effects of thyroid hormone supplementation on, 421
see also Neurodevelopmental outcome, neonatal
- Neonates, *see* Premature infants and entries beginning with terms: Neonatal, Perinatal, Postnatal
- Nervous system
 ACS effects on, 344
see also Fetal brain, transvaginal three-dimensional and Doppler US of; Neonatal brain and entries beginning with prefix: Neuro-
- Neurodevelopmental outcome, neonatal
 effects of hypothyroxinemia on, 420-421
see also Neurodevelopmental outcome of extremely premature infants
- Neurodevelopmental outcome of extremely premature infants, 351-356
 blindness in, 354-355
 CP prevalence in, 354
 deafness in, 355
 hypothyroxinemic, *see* Neurodevelopmental outcome of extremely premature infants, hypothyroxinemic
 impaired mental development in, 353-354
 limitations of data on, 352-353
 prevalence of disabilities in, 355-356
- Neurodevelopmental outcome of extremely premature infants, hypothyroxinemic, 420-423
 effects of thyroid hormone supplementation on, 421-423
- Neuromuscular blocking agents in pregnancy, pharmacokinetics and pharmacodynamics of simple reversible direct effects of, 126-127
- Neuromuscular effects, maternal, of beta-sympathomimetics, 324
- Nevirapine for HIV-1-infected pregnant women and their newborn infants, 171
- New anti-asthma drugs, 149-150
- New methods of preterm labor management, 272-291
 with cervical ripening inhibitors, 281-282
 with new tocolytics, *see* New tocolytic(s)
 reasons for, 272-273
- New tocolytic(s), 273-281
 COX-2 inhibitors as, *see* Cyclooxygenase-2 inhibitors
 K⁺ channel openers as, 231, 278-281
 nitric oxide as, 274-277
- Newborns, *see* Premature infants and entries beginning with terms: Neonatal, Postnatal
- NFκB (nuclear factor κ B), activation of, in GBS infection, effects of ibuprofen blockage of, on iNOS gene expression, 65-59
- Nicardipine, 230, 243, 244
- Nifedipine, as tocolytic, 230, 232, 265-270
 adverse and beneficial effects of, 316, 330, 331, 334, 335
 MgSO₄ compared with, 243, 244, 269, 276, 319, 321, 330, 331
 ritodrine compared with, 251, 267, 268, 331
 terbutaline compared with, 251, 331
- Nifedipine in pregnancy
 as antihypertensive, 127, 128, 160-163
see also Nifedipine, as tocolytic
- Nimesulide, 281
- Nitric oxide (NO), as tocolytic, 274-277
- Nitric oxide synthase (NOS)
 mRNA of inducible, in GBS infection, effects of ibuprofen blockage of NFκB activation on, 65-69
 postnatal endothelial, effects of antenatal dexamethasone on, 94-99
- L-Nitro-arginine methyl ester (L-NAME), 281
- Nitroglycerin, as tocolytic, 231, 274, 276, 277
- NO (nitric oxide), as tocolytic, 274-277
- Non-nucleoside reverse transcriptase inhibitors for HIV-1- infected pregnant women and their newborn infants, 171, 174
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 243, 257
see also specific nonsteroidal anti-inflammatory drugs
- Normal embryonic growth and anatomy, three-dimensional US of, in early pregnancy, 3-4
- NOS, *see* Nitric oxide synthase
- NSAIDs, *see* Nonsteroidal anti-inflammatory drugs
- NT, *see* Nuchal translucency
- Nuchal translucency (NT)
 in chromosomally abnormal 11-to-14-week fetus, Doppler US of, 34
 three-dimensional US measurement of, in early pregnancy, 6-7
- Nuclear factor κ (kappa) B (NFκB) in GBS infection, effects of ibuprofen blockage activation of, on iNOS gene expression, 65-59
- Nucleoside analogs for HIV-1-infected pregnant women and their newborn infants, 172-175
- Nucleoside reverse transcriptase inhibitors for HIV-1-infected pregnant women and their newborn infants, 171
- Nutrition
 effects of photoprotection of total parenteral nutrition solutions on infused total parenteral nutrition load and urinary

- excretion of peroxides in premature infants, 55-59
 - neonatal, IGFs in, 432
- Nylidrin, 329
- Observational studies of anti-asthma medications during pregnancy, 147
- Onset of term labor
 - endocrine control of, 224-226
 - historical perspective on, 223-224
 - mechanisms responsible for, 224
- Oral beta (β)-sympathomimetics, 251
- Oral drug administration, *see entries beginning with term*; Systemic
- Osteoporosis, steroid-induced osteoporosis, antenatal corticosteroids and maternal, 387
- Outcome
 - neonatal, *see Neonatal outcome*
 - of pregnancy in asthmatic women, 145-146
 - see also Drug(s) in pregnancy; Mortality; Outcome of extremely premature infants; Patient survival specific outcomes; for example: Fetal anomalies and malformations entries beginning with terms Neurodevelopmental outcome and specific conditions and therapeutic modalities*
- Outcome of extremely premature infants, 348-359
 - neurodevelopmental outcome, *see Neurodevelopmental outcome of extremely premature infants*
 - and prediction of mortality, 351
 - survival and, 349-351
- Oxcarbazepine in pregnancy, 156, 157
- Oxprenolol in pregnancy, 160
- Oxygen dependency, *see Incidence of oxygen dependency or death with antenatal TRH*
- Oxygenation, tissue, peripheral FOE and whole blood lactate as measures of, and guides to need for blood transfusions in premature infants, 60-64
- Oxytocin antagonists in pregnancy
 - effects of physiologic changes in pregnancy on metabolism of, 122
 - see also Atosiban*
- Palsy, *see Cerebral palsy, neonatal*
- Pancreas, PTHrP in development of, 82
- Parathyroid hormone-related protein (PTH-rP), role of, in development, 76-84
 - in bone formation and skeletal development, 80-81
 - in development of skin, hair, and teeth, 81-82
 - in mammary gland development and lactation, 81
 - modes of action of, 77-78
 - molecular biology and structure of PTH-rP, 76-77
 - of pancreas, fetal lungs, and amnion, 82
 - PTH-rP expression, *see mRNA, PTHrP*
 - role of PTH-rP in placenta, 81
- Parenteral nutrition, total, effects of
 - photoprotection of solutions of, on infused total parenteral nutrition load and urinary excretion of peroxides in premature infants, 55-59
- Parenteral steroids in pregnancy, 151
- Paroxetine during pregnancy and lactation, 183, 184
- Paternal risk factors for preterm labor, 211
- Patient survival
 - extreme prematurity and, 349-351
 - see also specific conditions*
- Penicillins in infection-mediated preterm delivery, 301-303
- Perinatal antiretroviral agents for HIV-1-infected pregnant and their newborn infants, 171-172
- Perinatal depression, incidence and phenomenology of, 178-180
- Perinatal period, IGFs in, 432
- Periodontal disease, maternal, preterm labor and, 205, 210
- Peripheral fractional oxygen extraction (FOE), whole blood lactate and, as measures of tissue oxygenation and guide to need for blood transfusions in premature infants, 60-64
- Peroxides, effects of photoprotection of total parenteral nutrition solutions on infused total parenteral nutrition load and urinary excretion of, in premature infants, 55-59
- PGE₂ (prostaglandin E₂) receptors in fetal and newborn ductus arteriosus, 70-75
- P-glycoprotein, transplacental transport of digoxin by, 198-200
- Pharmacokinetics
 - maternal, of antiretroviral drugs for HIV-1 infection, 172-173
 - of MgSO₄, 237-238
 - see also Pharmacokinetics and pharmacodynamics in pregnancy*
- Pharmacokinetics and pharmacodynamics in pregnancy, 124-132
 - of antihypertensive drugs, 161-162
 - of biophase distribution, 127-128
 - of indirect drug effects, 128-130
 - maternal, of antiretroviral agents, fetal risk and, 172-173
 - of receptor binding, 127
 - signal transduction model, 130-131
 - of simple reversible direct drug effects, 125-127
- Pharmacological management, *see Drug(s) in pregnancy*
- Pharmacology
 - of ACSs, 342
 - of beta-sympathomimetics, 249-250
 - of calcium channel blockers, 265
 - of COX-2 inhibitors, 260
 - see also specific drugs*
- Phenobarbital in pregnancy, 154, 156, 157, 192
- Phenomenology of perinatal depression, 178-180
- Phenytoin in pregnancy, 139-140, 154, 156, 157, 192, 193
- Phosphonomethoxy propyladenine (PMPA) for HIV-1-infected pregnant women and their newborn infants, 173
- Photoprotection of total parenteral nutrition solutions, effects of, on infused total parenteral nutrition load and urinary

- excretion of peroxides in premature infants, 55-59
- Physical properties of fetal DV, 14
- Physiological changes in pregnancy, effects of
 - on drug distribution, 120-123
 - see also* Physiological changes in pregnancy, effects of, on diseases
- Physiological changes in pregnancy, effects of, on diseases, 139-143
 - of carbohydrate metabolism changes, 142
 - of cardiovascular changes, 140-141
 - of gastrointestinal changes, 143
 - of hematologic changes, 139-140
 - of renal changes, 141-142
 - of respiratory changes, 143
- Physiological importance of blood shunting through ductus venosus, 11-12
- Physiology
 - of ACSs, 342
 - see also* entries beginning with term: Physiological
- Pinacidil, 280, 281
- Pindolol in pregnancy, 160
- Piperacillin in infection-mediated preterm delivery, 303
- Placebo, MgSO₄ efficacy against, 240-241
- Placenta, PTHrP in, 81
- Placental drug transport, 197-200
 - of digoxin by P-glycoprotein, 198-199
 - implications of, in fetal tachycardia management, 199-200
- Placental transfer of antihypertensive drugs, 161
- PMPA (phosphonomethoxy propyladenine) for HIV-1-infected women and their newborn infants, 173
- Postnatal antiretroviral agents for HIV-1-infected pregnant and their newborn infants, 174-175
- Postnatal dexamethasone in premature infants, 378-379
- Postnatal endothelial nitric oxide synthase (eNOS), effects of antenatal dexamethasone on, 94-99
- Postnatal life, early, function of insulin in, 436-439
- Postnatal steroids to prevent CLD in premature infants, 378-379, 397-405
 - future research on, 404
 - inhaled, 403
 - systemic, *see* Systemic steroids, postnatal, to prevent CLD in premature infants
- Postnatal thyroid hormone replacement in extremely premature infants, 417-425
 - effects of thyroid hormone supplementation of thyroid hormone concentrations, 423
 - neurodevelopmental outcome and, *see* Neurodevelopmental outcome of extremely premature infants, hypothyroxinemic thyroid function in premature infant and, 419-420
 - thyroid hormone production and metabolism during fetal life and, 417-419
 - trials with, 421-423
- Postpartum depression (PPD), 178-182
 - impact of, 181-182
- Potassium ion (K⁺) channel openers for preterm labor, 231, 278-281
- PPD, *see* Postpartum depression
- Prazosin in pregnancy, 160
- Preclinical evidence, 180-182
 - for depression impact during pregnancy, 180-181
 - for PPD impact, 181-182
- Prednisone in pregnancy, 149, 194
- Pregnancy, *see* Drug(s) in pregnancy and specific aspects of pregnancy
- Pregnancy failure, *see* Abortion
- Premature (preterm) infants
 - effects of photoprotection of total parenteral nutrition solutions on infused total parenteral nutrition load and urinary excretion of peroxides in, 55-59
 - extremely, *see* Insulin therapy in extremely premature infants; Outcome of extremely premature infants; Postnatal thyroid hormone replacement in extremely premature infants
 - whole blood lactate and peripheral FOE, as measures of tissue oxygenation and guides to need for blood transfusions in, 60-64
 - see also* Hypothalamic-pituitary-adrenal axis in premature infants; Prematurity
- Premature rupture of membranes (PROM), antibiotics for, 302-304
- Prematurity
 - inhaled low (0.5%-1.5%) CO₂ for apnea of, 100-106
 - see also* Antenatal corticosteroids for preterm labor and birth; Premature infants and entries beginning with term: Preterm
- Prenatal conditions and interventions, *see* Fetus
- Preterm birth, infection-mediated, 295-309
 - antibiotics for, *see* Antenatal antibiotics for infection-mediated preterm labor and birth
 - bacterial products in, 296
 - cytokines in, 296-297
 - fetal infections, *see* Fetal infections, preterm labor and birth and
 - maternal, *see* Reproductive tract infections, preterm labor and birth and
- Preterm labor
 - idiopathic, 146
 - see also* Epidemiology of preterm labor; Premature infants; Preterm labor management; Risk(s) for preterm birth; Systematic approach to preterm labor
- Preterm labor management
 - introduction to, 203, 263
 - systemic approach to, 231-232
 - see also* Alternative approach(es) to preterm labor; Antenatal antibiotics for infection-mediated preterm labor and birth; Antenatal corticosteroids for preterm labor and birth; Expectant management of preterm labor; New methods of preterm labor management; Preterm birth, infection-mediated; Tocolysis

- Prevalence
of CP in extreme prematurity, 354
of neurodevelopmental disabilities in extreme prematurity, 355-356
see also Incidence and specific conditions
- Prevention
of CLD in premature infants, *see* Postnatal steroids
to prevent CLD in premature infants
EOGBS, implementation of guidelines on, 107-113
of hyperglycemia in extremely premature infant with insulin therapy, 439-440
of infection-mediated preterm birth with antibiotics, 299-301; *see also* Antenatal antibiotics for infection-mediated preterm labor and birth
of neonatal lung disease, *see* Antenatal thyrotropin-releasing hormone in prevention of neonatal lung disease
of preterm labor, systematic approach to, 231-232; *see also* Preterm labor management
of virilization in 21- or 11-hydroxylase deficiency premature female fetus, 379
- Primidone in pregnancy, 154, 156, 157
- Prior history of preterm labor, preterm labor and, 205
- PROM (premature rupture of membranes), antibiotics for, 302-304
- Propafenone, placental transport of, 199
- Prostaglandin E₂ (PGE₂) receptors in fetal and newborn ductus arteriosus, 70-75
- Prostaglandin synthetase inhibitor(s), 256-262
COX-2 inhibitors as, *see* Cyclooxygenase-2 inhibitors
indomethacin as, *see* Indomethacin
long-term, 311, 312
see also Prostaglandin synthetase inhibitor(s), effects of
- Prostaglandin synthetase inhibitor(s), effects of, 230, 232, 257-259, 334, 335
clinical efficacy of, 257, 326
of cyclooxygenase-2 inhibitors, 260-261
fetal effects of, 327-330
of indomethacin, 258, 259, 325-330
maternal effects of, 327
- Protamine sulfate in pregnancy, 166
- Protease inhibitors for HIV-1-infected pregnant women and their newborn infants, 171, 172, 174-175
- PTH-rP, *see* Parathyroid hormone-related protein, role of, in development
- Pulmonary effects of beta-sympathomimetics, 253
- Pulsatile blood flow velocity in fetal DV, three-dimensional and Doppler US of, 14-16
- Quinidine, placental transport of, 199
- Race, preterm labor and, 205, 206
- RDS (respiratory distress syndrome), antenatal TRH effects on incidence of, 410
- Receptors, drug binding by, in pregnancy, 127
- Recommendations on drug therapy in pregnancy
on anti-asthma therapy, 150-151
on antihypertensive therapy, 163
- Regimen, fetal corticosteroid, 386-390
- Relaxin, 280
- Renal changes in pregnancy, effects of, on diseases, 141-142
- Renal disease, effects of renal changes on, in pregnancy, 141-142
- Renal effects of beta-sympathomimetics, 253
- Reproductive tract infections, preterm labor and birth and, 205-207
lower, 298-299
see also Preterm birth, infection-mediated
- Research on MgSO₄, 322
- Resistance, multidrug resistance 1-type P glycoprotein in placental drug transport, 199
- Respiratory changes in pregnancy, effects of, on diseases, 143
- Respiratory distress syndrome (RDS), antenatal TRH effects on incidence of, 410
- Reversible direct drug effects, simple, in pregnancy, pharmacokinetics of, 125-127
- Risk(s)
of multiple fetal corticosteroid courses, 388-390
of postnatal systemic steroids to prevent CLD in premature infants, 398-402
see also Risk(s) for preterm birth; Safety and risks
- Risk(s) for preterm birth
infections as, 299; *see also* Preterm birth, infection-mediated
paternal risk factors, 211
see also Epidemiology of preterm labor; Risk(s) for preterm birth, assessment of
- Risk(s) for preterm birth, assessment of, 215-222
cervical length as, 216-217
with fetal fibronectin, 205, 217-218
with HUAM, 219-220, 310-311
with salivary estriol, 205, 218-219
- Ritodrine, 230, 232, 248, 267-269, 283
adverse and beneficial effects of, 322, 323
atosiban compared with, 251, 333
indomethacin compared with, 251
intravenous, 250
long-term, 311-312
MgSO₄ compared with, 242-243, 319, 321
nifedipine compared with, 251, 267, 268, 331
NO compared with, 275-277
pharmacokinetics of, 128
pharmacology of, 249-250
- Ritonavir for HIV-1-infected women and their newborn infants, 171, 174
- Rupture of membranes, premature, antibiotics for, 302-304
- S. agalactiae* (*Streptococcus agalactiae*) infection, *see* Group B streptococcus infection
- Safety and risks
of insulin therapy in extremely premature infants, 443-444
of systemic steroids in prevention of CLD in extremely premature infants, 398-401

- of three-dimensional US in early pregnancy, 8-9
see also Risk(s); Safety and risks of drug therapy in pregnancy and entries beginning with terms: Adverse and beneficial effects
- Safety and risks of drug therapy in pregnancy
 - of anti-asthma medications, 146-150
 - of antihypertensive therapy, 162-163
 - of antiretroviral drugs for HIV-1 infection, 172-173
 - of widespread use of antenatal antibiotics, 304
see also Drug(s) in pregnancy; Fetal effects of drugs; Maternal effects of tocolysis; Neonatal effects of drugs in pregnancy and entries beginning with terms: Adverse and beneficial effects
- Salbutamol, 230, 277, 333
- Salicylate
 - effects of, on bilirubin and albumin binding, 52
see also Aspirin in pregnancy
- Salivary estriol in preterm labor risk assessment, 205, 218-219
- Salmeterol, inhaled, in pregnancy, 150
- Saquinavir for HIV-1-infected women and their newborn infants, 171
- Saturation binding of PGE₂ receptors in fetal and neonatal DA, 72
- SCN, *see* Suprachiasmatic nucleus, fetal
- Screening for CAH in premature infants, 379-380
- Seizures
 - frequency of, pregnancy effects on, 154
see also Antiepilepsy drugs in pregnancy
- Selective serotonin reuptake inhibitors (SSRIs)
 - during pregnancy and lactation, 177, 183-185
- Sertraline during pregnancy and lactation, 184, 185
- Serum binding capacity, cord blood, for bilirubin in neonatal jaundice, 51
- Shunt, *see* Umbilical venous blood shunting through fetal DV, three-dimensional US of
- Signal(s) entraining fetal SCN, 367-368
- Signal transduction
 - of drug effects in pregnancy, model of, 130-131
 - of insulin and IGFs, effects of defective, 431
- Simple reversible direct drug effects in pregnancy, 125-127
- Single antenatal corticosteroid (ACS) course, adverse and beneficial effects of, 342-343
- Skeletal development, role of PTHrP in, 80-81
- Skin, PTHrP in development of, 81-82
- Socioeconomic status, maternal, preterm labor and, 205, 209
- Sodium nitroprusside, 274
- Sono-angiography, three-dimensional, of fetal brain circulation, 40-41
- Sonography, *see* Three-dimensional and Doppler ultrasound
- Sotalol, transplacental therapy with, 197
- Spontaneous abortion, identification of, with three-dimensional US, 7-8
- SSRIs (selective serotonin reuptake inhibitors)
 - during pregnancy and lactation, 177, 183-185
- Stable isotopes, use of, in studies of drug metabolism in pregnancy, 133-138
- Stavudine in pregnancy, 171
- Steroid(s), *see* Corticosteroids in pregnancy; Fetal and neonatal hormonal therapy; Hypothalamic-pituitary-adrenal axis in premature infants; Postnatal steroids to prevent CLD in premature infants and entries beginning with terms: Antenatal corticosteroids
- Steroid-induced osteoporosis, maternal, antenatal corticosteroids and, 387
- Streptococcus agalactiae* infection, *see* Group B streptococcus infection
- Structure
 - of PTH-rP, 76-77
see also Structure, fetal brain, three-dimensional and Doppler US of
- Structure, fetal brain, three-dimensional and Doppler US of, 40-42
 - of brain volume, 41-42
 - multiplanar fetal intracranial structure, 39-40
- Subcutaneous beta (β)-sympathomimetics, 250-251
- Substance abuse, maternal, preterm labor and, 205, 208
- Succinylcholine in pregnancy, 126-127
- Sulbactam in infection-mediated preterm delivery, 302, 303
- Sulindac, 326, 329
- Supplementation, *see* Postnatal thyroid hormone replacement in extremely premature infants
- Suprachiasmatic nucleus (SCN), fetal
 - development of, 364-365
 - functional mechanisms of, 363-364
 - signals entraining, 367-368
- Surface of fetal head, Doppler US of, 39
- Survival of extremely premature infant, 349-351
- Sympathomimetics, *see* Beta-sympathomimetics in pregnancy
- Systematic approach to preterm labor, 223-235
 - causes of preterm labor, 226-227; *see also* Epidemiology of preterm labor; Preterm birth, infection-mediated; Risk(s) for preterm birth
 - to management of preterm labor, 231-232
 - onset of term labor and, *see* Onset of term labor predicting, 227-229
 - to prevention, 229-231
- Systemic steroids
 - in pregnancy, 116, 145, 147, 149, 150
see also Systemic steroids, postnatal, to prevent CLD in premature infants
- Systemic steroids, postnatal, to prevent CLD in premature infants, 398-401
 - assessing need for, 398
 - safety and risks of, 398-401
- Systemic theophylline in pregnancy, 150
- T3 (triiodothyronine), *see* Postnatal thyroid hormone replacement in extremely premature infants
- T4 (thyroxine), *see* Postnatal thyroid hormone replacement in extremely premature infants
- Tachyarrhythmia, fetal, 196-197
see also Transplacental therapy of fetal tachycardia

- Tachycardia, fetal, *see* Transplacental therapy of fetal tachycardia
- Tacrolimus, placental transport of, 199
- Teeth, PTHrP in development of, 81-82
- Terbutaline, as tocolytic, 230, 248, 267-269
- atosiban compared with, 251, 333
 - indomethacin compared with, 251
 - long-term, 312
 - MgSO₄ compared with, 241-243, 251, 319, 321
 - nifedipine compared with, 251, 331
 - pharmacology of, 249-250
 - subcutaneous, 250-251
- Terbutaline in pregnancy
- for acute asthma, 151
 - see also* Terbutaline, as tocolytic
- Term labor, *see* Onset of term labor
- Tetracyclines in pregnancy, 142
- Thalidomide, fetal and neonatal effects of, 191, 194
- Theophylline in pregnancy, 145, 148, 150, 151
- Therapy and management, *see* Drug(s) in pregnancy; Preterm labor management; Prevention *specific therapeutic modalities and conditions*
- Thiazide diuretics in pregnancy, 160
- Three-dimensional (3D) and Doppler ultrasound (US)
- introduction to, 1-2
 - see also* Early pregnancy, three-dimensional US in; Fetal brain, transvaginal three-dimensional and Doppler US of; Fetal venous system, Doppler US of; Umbilical artery, fetal, Doppler velocimetry of
- Thrombosis, *see* Antithrombotic therapy in pregnancy
- Thyroid function in extremely premature infants, 419-420
- Thyroid hormone replacement in extremely premature infants, *see* Postnatal thyroid hormone replacement in extremely premature infants
- Thyrotropin-releasing hormone (TRH)
- in pregnancy, 128-130
 - see also* Antenatal thyrotropin-releasing hormone in prevention of neonatal lung disease
- Thyroxine, *see* Postnatal thyroid hormone replacement in extremely premature infants
- Tiagabine in pregnancy, 157
- Time course of simple reversible direct drug effects in pregnancy, 126-127
- Timing of antenatal corticosteroids for fetal maturation, 390
- Tissue oxygenation, peripheral FOE and whole blood lactate, as measures of, and guides to need for blood transfusions in premature infants, 60-64
- Tocolysis, 229-232
- long-term, 311-313
 - see also* Tocolytic(s)
- Tocolytic(s)
- adverse and beneficial effects of, *see* Adverse and beneficial effects of tocolysis
 - beta-sympathomimetics as, *see* Beta-sympathomimetics, as tocolytics
 - with calcium channel blockers, *see* Calcium channel blockers, as tocolytics
 - effects of physiologic changes of pregnancy on metabolism of, 122
 - magnesium sulfate as, *see* Magnesium sulfate
 - prostaglandin synthetase inhibitors as, *see* Prostaglandin synthetase inhibitor(s)
 - see also* New tocolytic(s)
- Tone of fetal ductus arteriosus, PGE₂ receptor effects on, 71-72
- Topiramate in pregnancy, 154, 157
- Total congenital malformations due to anti-asthma medications, 148-149
- Total parenteral nutrition (TPN) solutions, effects of photoprotection of, on infused load of, and urinary excretion of peroxides in premature infants, 55-59
- Transduction, signal transduction model of drugs effects in pregnancy, 130-131
- Transfusions, blood, in premature infants, whole blood lactate and peripheral FOE, as measures of tissue oxygenation and guides to need for, 60-64
- Translucency, nuchal, *see* Nuchal translucency
- Transplacental therapy of fetal tachycardia, 196-201
- described, 196-197
 - management options in, 197
 - pharmacological, outcome and, 197
 - placental drug transport and, *see* Placental drug transport
- Transvaginal Doppler, *see* Fetal brain, transvaginal three-dimensional and Doppler US of
- TRH, *see* Thyrotropin-releasing hormone
- Tricyclic antidepressants during pregnancy and lactation, 116, 183
- Triiodothyronine, *see* Postnatal thyroid hormone replacement in extremely premature infants
- Trimethadione, fetal and neonatal effects of, 193
- 24- to 30-Week premature infants, HPA axis in, 375-377
- 26 weeks after birth, oxygen dependency or death with antenatal TRH at, 411-412
- 28 days after birth, oxygen dependency or death with antenatal TRH at, 410-411
- UH (unfractionated heparin) in pregnancy, 166
- Ultrasound, *see* Three-dimensional and Doppler ultrasound
- Umbilical artery, fetal, Doppler velocimetry of, 44-47
- in high-risk pregnancies, 45-46
 - intrapartum, and in low-risk pregnancies, 46
- Umbilical vein, fetal
- Doppler US of, 22-23
 - see also* Umbilical venous blood shunting through fetal DV, three-dimensional US of
- Umbilical venous blood shunting through fetal DV, three-dimensional US of, 11-13
- degree of, 11
 - physiologic importance of, 11-12
 - regulation of, 12-13

- Unfractionated heparin (UH) in pregnancy, 166
- Urinary excretion of peroxides, effects of
photoprotection of total parenteral nutrition
solutions on infused total parenteral
nutrition load and, in premature infants, 55-
59
- US (ultrasound), *see* Three-dimensional and
Doppler ultrasound
- Uterine activity monitoring, home, for preterm
labor, 219-220, 310-311
- Uterine malformations, preterm labor and, 205, 208
- "Uterine muscle hyperreactivity" (idiopathic
preterm labor), 146
- Valproic acid in pregnancy, 154-156, 192
- Velocimetry, *see* Umbilical artery, fetal, Doppler
velocimetry of
- Velocity, blood flow, *see* Ductus venosus, fetal, three-
dimensional and Doppler US of blood flow
velocity in; Umbilical artery, fetal, Doppler
velocimetry of; Umbilical venous blood
shunting through fetal DV, three-dimensional
US of
- Vena cava, fetal inferior, Doppler US of, 25-26
- Venous system, *see* Fetal venous system, Doppler US
of
- Verapamil, 160, 197, 199, 230
- Very low-birth weight infants, *see* Premature infants
- Vigabatrin in pregnancy, 157
- Vinca alkaloids, placental transport of, 199
- Virilization in 21- or 11-hydroxylase-deficient
premature female fetus, dexamethasone in
prevention of, 379
- Vitamin K, 156
- VLBW (very low-birth weight) infants, *see* Premature
infants
- Voltage dependent K^+ (K_v) channel, 279
- Volume, fetal brain, three-dimensional and Doppler
US of, 41-42
- Warfarin in pregnancy, 165-166
- Waveform analysis of fetal DV with three-
dimensional and Doppler US, 16-17
- Whole blood lactate, peripheral FOE and, as
measures of tissue oxygenation and guides to
need for blood transfusions in premature
infants, 60-64
- Widespread use of antibiotics for preterm labor and
birth, risks of, 304
- Work and employment, maternal, preterm labor
and, 205, 209
- Yolk sac, three-dimensional US of, in early
pregnancy, 7-8
- Zafirlukast in pregnancy, 150
- Zalcitabine for HIV-1-infected women and their
newborn infants, 171
- Zidovudine for HIV-1-infected women and their
newborn infants, 171, 173, 174
- Zileuton in pregnancy, 150
- Zonisamide in pregnancy, 156, 157

